Insmed reported $-370.02M in Net Income for its fiscal quarter ending in September of 2025.





Net Income Change Date
BioMarin Pharmaceutical USD -30.74M 271.28M Sep/2025
Cytokinetics USD -306.18M 171.81M Sep/2025
DBV Technologies USD -33.16M 8.71M Sep/2025
Dynavax Technologies USD 18.72M 114.82M Jun/2025
Gilead Sciences USD 3.05B 1.09B Sep/2025
Insmed USD -370.02M 48.34M Sep/2025
Novartis USD 3.93B 113M Sep/2025
Regeneron Pharmaceuticals USD 844.6M 615.4M Dec/2025
Sarepta Therapeutics USD -179.95M 376.84M Sep/2025
Ultragenyx Pharmaceutical USD -180.41M 65.46M Sep/2025
Vertex Pharmaceuticals USD 1.08B 50M Sep/2025